Initial study of FGF 23 measurement by LIAISON FGF 23 method
Authors:
B. Friedecký 1; J. Vávrová 1; L. Pavlíková 1; S. Dusilová Sulková 2; V. Palička 1
Authors place of work:
ÚKBD, Fakultní nemocnice, Hradec Králové
1; Hemodialyzační středisko, Fakultní nemocnice, Hradec Králové
2
Published in the journal:
Klin. Biochem. Metab., 26, 2018, No. 1, p. 18-20
Summary
Objectives:
Differences in measurement of FGF 23 in serum, EDTA plasma and heparin plasma
Method:
Fully automated neasurement of intact FGF 23 by DiaSorin LIAISON FGF 23 method. The samples of serum, EDTA plasma and heparin plasma were used.
Results:
Serum values of FGF 23 are ca 3 times lower than EDTA and heparin plasma. Values in EDTA and heparin plasma are comparable. Phosphate values are comparable in serum and both plasma samples, but Ca values cannot be determined by phohotometric method in EDTA plasma. In hemodialyzed patients are all results higher than upper reference limit, often on 2-3 times higher numerical order and in very wide range. Patients after transplantation had in approximately 50 % cases FGF 23 values above upper reference limit.
Discussion:
There is possible to use for FGF 23 measurement alternatively EDTA or heparin plasma samples. Using of EDTA plasma samples, recommended by producer requires separately collected sample for Ca measurement.
Keywords:
FGF 23, serum, EDTA plasma, heparin plasma.
Zdroje
1. Lu, X., Hu, M. C. Klotho/FGF 23 axis in chronic kidney disease and cardiovascular disease. Kidney Dis (Basel), 2017, 3, p. 15-23
2. Courbebaise, N., Lanske, B. Biology of fibroblast growth factor 23: From physiology to pathology. Cold Spring Harb Perspect Med 2017, doi: 0.1101/csperspect.a031260.
3. Souberbielle, J. C., Prié, D., Piketty, M. L., Rothesbuhler, A., Delanghe, P., Chanson, P., Cavalier, E. Evaluation a fully automated assay for plasma intact FGF 23. Calcif Tissue Int., doi:10.1007/s00223-017-0307-y)
4. Smith, E. R., McMahon, L. P., Holt, S. G. Method specific differences in lasma fibroblast growth factor 23 measurement using four commercial ELISAs. Clin. Chem. Lab. Med. 2013, 51, p. 1971-1981
5. Friedecký, B., Vávrová, J. Harmonizace stanovení kostních markerů. Analytické minirewiew. Klinická Biochemie a Metabolismus. Klin. Biochem. Metab., 25 (46), 2017, No. 4, p. 162-166
6. KDIGO 2017 Clinical Practice Guideline Update for the dia-gnosis, evaluation, prevention and treatment of chronic kidney disease-mineral and bone disorder (MBD). Kidney International supplements, 2017, 7, p. 1-59.
7. Schleck, M. L., Souberbille, J. C., Delanaye, P., Plebani, M., Cavalier, E. Parathormon stability in hemodialyzed patients and healthy subjects:Comparison on centrifuged EDTA and serum samples with second and third generation assays. Clin. Chem. Lab. Med., 2017, 55, p. 1152-1159.
Štítky
Clinical biochemistry Nuclear medicine Nutritive therapistČlánok vyšiel v časopise
Clinical Biochemistry and Metabolism
2018 Číslo 1
Najčítanejšie v tomto čísle
- Determination of Carbohydrate Deficient Transferrin (CDT) by various analytical techniques
- Vitamin K and its importance in laboratory medicine
- Online solid phase extraction analytical system coupled to tandem mass spectrometry for clinical applications.
- Initial study of FGF 23 measurement by LIAISON FGF 23 method